Screener
Supernus Pharmaceuticals SUPN Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts receivable, net | 182,183 | 187,802 |
| Inventories, net | 87,062 | 82,385 |
| Prepaid expenses and other current assets | 78,094 | 65,325 |
| Total current assets | 731,580 | 644,182 |
| Restricted cash | 1,450 | 1,450 |
| Property and equipment, net | 10,042 | 10,531 |
| Intangible assets, net | 549,712 | 569,456 |
| Goodwill | 120,668 | 124,882 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's total current assets?
- Supernus Pharmaceuticals (SUPN) reported total current assets of $731.58M in Q1 2026.
- How has Supernus Pharmaceuticals's total current assets changed year-over-year?
- Supernus Pharmaceuticals's total current assets increased by 6.4% year-over-year, from $687.58M to $731.58M.
- What is the long-term trend for Supernus Pharmaceuticals's total current assets?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's total current assets has grown at a 0.4% compound annual growth rate (CAGR), from $630.42M to $644.18M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Supernus Pharmaceuticals's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude